# Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study

> **NCT05295394** · PHASE4 · WITHDRAWN · sponsor: **Pedro Cahn**

## Conditions studied

- HIV-1 Infection

## Interventions

- **DRUG:** Dolutegravir plus lamivudine

## Key facts

- **NCT ID:** NCT05295394
- **Lead sponsor:** Pedro Cahn
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2019-05-22
- **Primary completion:** 2022-08
- **Final completion:** 2022-08-30
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Low recruitment, We did not find participants with the M184V mutation , inclusion criteria , throughout 230 resistance tests carried out
- **Last updated:** 2022-04-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05295394

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05295394, "Dolutegravir-Lamivudine as Dual Therapy in naïve HIV-Infected Patients With Documented M184V Mutation:A Pilot Study". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT05295394. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*